NEW YORK (GenomeWeb) – Cancer Genetics said today that it has been hired by Effector Therapeutics to provide clinical biomarker services for Effector's lead product candidate, eFT508 — a highly selective oral small molecule inhibitor of MNK1 and MNK2.